Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

23-valent pneumococcal capsular polysaccharide vaccine

Known as: 23-valent vaccine, pneumococcal polysaccharide PPV23, PCV 23 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract Older adults, particularly those with chronic obstructive pulmonary disease, are advised to receive 23-valent… Expand
2017
2017
Introduction Les patients suivis pour une maladie systemique et traites par immunosuppresseurs sont a risque eleve d’infection… Expand
2016
2016
ABSTRACT Introduction: Diseases caused by Streptococcus pneumoniae are a major public health problem worldwide, which can be… Expand
Review
2015
Review
2015
BACKGROUND Currently, one lifetime booster of a 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for those at… Expand
  • figure 1
  • table 1
  • table 2
2014
2014
The current study examined the safety and immunogenicity of 23-valent pneumococcal capsular polysaccharide vaccine (Pneumo23… Expand
Review
2012
Review
2012
Purpose of review Pneumococcal glycoconjugate vaccines (PCVs) are now widely used in infant immunization schedules. These… Expand
Review
2012
Review
2012
For the influenza pandemic of 2009-2010, countries responded to the direct threat of influenza but may have missed opportunities… Expand
  • figure 1
  • table 1
  • table 2
  • table 2
Highly Cited
2010
Highly Cited
2010
This study evaluated safety & immunogenicity of ZOSTAVAX® (zoster vaccine: ZV) administered concomitantly versus nonconcomitantly… Expand
2008
2008
We compared the effect of intramuscular vs. inhaled 23-valent pneumococcal capsular polysaccharide vaccine (23-PPV) on pulmonary… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2